Abstract
signalling has been associated with many cancers, and the development of new therapeutic agents targeting EGFR has attracted attention [5, 6] . In colorectal cancer, EGFR overexpressed in 65-70% of tumours, and the extent of EGFR expression showed a positive correlation with poor prognosis [7] . Interestingly, it was reported that the Aurora-A protein occurred in approximately 50-70% of patients with colorectal cancer. There was also a trend that patients with negative expression of Aurora-A protein showed slightly better survival rates than those with positive protein expression in stage III colorectal cancer [8, 9] .
Because EGFR and Aurora-A are all important prognosis indicators in cancer development, it would be interesting to analyse the relationship between EGF signalling and the activation of Aurora-A expression in cancers.
Controlling the translation of mRNA is a fundamental event in many aspects of cell metabolism. It organizes a critical step for the control of gene expression, and hence cell growth, proliferation and differentiation [10] . [11] . Because the activation of mTOR can mediate the translation of mRNAs which are related to cell cycle progression, cell survival, metastasis and angiogenesis, the deregulation of PI3K/Akt/mTOR may result in tumorigenesis and metastasis [12] . 1640 . All media were supplemented with 10% foetal bovine serum (FBS) , 100 g/ml streptomycin and 100 U/ml penicillin. In this series of experiments, cells were treated with 60 ng/ml (10 nM) EGF in optimal serum-free conditions.
It was reported that the PI3K/Akt/mTOR (mammalian target of rapamycin [mTOR]) signalling pathway deeply affects mRNA translation through the phosphorylation of downstream targets such as eukaryotic initiation factor 4E (eIF4E)-binding protein (4E-BP) and ribosomal protein S6 kinase (S6K)

Two kinds of EGFR signalling pathways were proposed to mediate the EGF effects. One is the traditional EGFR signalling pathway and the other is the nuclear EGFR signalling pathway. In our previous report, the treatment of EGF can increase Aurora-A gene expression through the nuclear EGFR signalling pathway, where the EGFR translocated into the nucleus to act as a transcriptional activator [13]. However, it is still interesting to check whether the activation of traditional EGFR signalling pathway possesses the ability to transactivate the Aurora-A gene. In the present study, we demonstrate that traditional EGFR signalling pathway increased the protein expression level of Aurora-A through activation of the translational machinery by the ERK and Akt pathways. A specific splicing variant of Aurora-A mRNA is responsible for increasing translational efficiency under EGF stimulation. Overall, our studies provide new insights into the regulation of Aurora-A overexpression in cancers.
Materials and methods
Cell culture and drug treatment
LS174T cells were cultured in minimum essential medium ␣ (MEM-␣, GIBCO, Invitrogen, Carlsbad, CA, USA). SW480 and SW620 cells were cultured in Leibovitz's L-15 medium (L-15, GIBCO). HT29 and HCT116 cells were cultured in RPMI medium
Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and RT-PCR
The qRT-PCR and RT-PCR reactions were performed as described previously [13] 
In vivo and in vitro translation assay
The in vivo translation assay was performed as described previously [14] . [14] . The in vitro translation assay was performed as described previously [14] . Briefly, the fragments contained Aurora-A mRNA 5ЈUTR and luciferase gene were subcloned into pGEM-7Z vector. After linearizing, these constructs were used to perform the in vitro transcription assay using the SP6 polymerase according to the manufacturer's instructions (Promega) . Equal amount of RNA was incubated with 10 g EGF-treated or untreated LS174T lysate, respectively. Then in vitro translation assay in rabbit reticulocyte lysates (Promega) was performed as described previously [14] .
Immunohistochemistry
An immunohistochemical assay was performed as previously described [15] [13] . In that study, we observed that the Aurora-A mRNA increased after long-term EGF stimulus in A431 cells (at least 18 hrs) [13] ; however, the protein expression of Aurora-A was induced in a biphase manner, which increased after 2 and 24 hrs EGF treatment (Fig. 1A) . Therefore, Fig. 1E [5] [6] . Total lysates were harvested for performing the Western blotting analysis by using the indicated antibodies. (Fig. 3A) . Blocking the ERK and Akt signal pathways, which regulated the Aurora-A protein expression upon EGF treatment (Fig. 1F) , showed no effects on Aurora-A mRNA expression (Fig. 3B) . In addition, the promoter activity of the Aurora-A gene was also not activated in response to EGF stimulus (Fig. 3C) . Furthermore, cells were pre-treated with actinomycin D to block the transcriptional activity, and the protein expression level of Aurora-A under EGF treatment was further increased (Fig. 3D) (Fig. 5B) . Interestingly, the ERK inhibitor, U0126, showed no effects on mTOR pathway (Fig. 5C, lanes 3 and 4) (Fig. 6A) . By using the (Fig. 6C ). To further demonstrate the exon 2 fragment is responsible for EGF-induced translational activation, the in vivo and in vitro translation assay were performed. From  Fig. 6D , the specific exon 2-contained fragments increased the (Fig. 6E) . The S6-IP assay further showed the increased association of the exon 2 containing construct with ribosomal complex after EGF stimulation (Fig. 6E) 
Results
Traditional EGF signalling pathway increases Aurora-A expression in EGFR-overexpressed cells through ERK and Akt signalling pathways
In our previous report, the EGF signaling enhanced the transcriptional activity of Aurora-A gene through the nuclear EGFR signaling pathway in EGFR-overexpressed A431 cell was demonstrated
we concluded that the nuclear EGFR signalling pathway, where the nuclear EGFR serves as a transcriptional coactivator, contributed to the increase expression of Aurora-A after EGF treatment for 24 hrs but not 2 hrs. This result prompts us to speculate whether traditional EGFR signalling pathway regulates the protein expression of Aurora-A in the early stage of EGF stimulus in EGFR-overexpressed cells. To address it, Western blot analysis was performed to examine the expression levels of five cultured human colorectal cell lines, which are all mediating the EGF signal through the traditional EGFR signalling pathway (Fig. 1B). The Aurora-A expression was observed in all of these colorectal cell lines, and the EGFR was overexpressed in four of these cell lines (Fig. 1B). Interestingly, the expression level of Aurora-A was enhanced by EGF stimulation only in those EGFR-overexpressed cell lines (Fig. 1B). To further characterize this phenomenon, LS174T cells were treated with EGF, and the cell lysate was collected for Western blot analysis. It showed that the expression of Aurora-A appears to increase via time-and dose-dependent manners (Fig. 1C). This phenomenon was abolished by pre-treating cells with an EGFR inhibitor, AG1478, to block the EGF signalling pathway (Fig. 1D). Moreover, it is interesting to examine which signalling pathways mediated the EGF-enhanced Aurora-A expression. As shown in
min., followed by treatment with EGF for 2 hrs. The expressions of Aurora-A and EGFR were analysed as in (B). (E) EGF-stimulated cells were harvested at the indicated times, and the expressions of EGFR, Aurora-A, p-Akt, Akt, p-ERK, ERK and ␣-tubulin were analysed. (F) Cells were pre-treated with U0126 or wortmannin for min., followed by EGF treatment for 2 hrs (DMSO, vehicle control). ␣-Tubulin was used as the loading control. (G) The induction of Aurora-A by short-term (2 hrs) EGF treatment was inhibited by U0126. Serum-starved A431 cells were pre-treated without (lanes 2, 5) or with (lanes 3, 6) U0126 (10 M) for min. and then treated without (lanes 1, 4) or with EGF (10 nM) for 2 (lanes 2-3) or 24 hrs (lanes
Fig. 1 EGF increases the expression level of Aurora-A through the activation of ERK and Akt signalling pathways in human colorectal cancer cell lines. (A) The expression of Aurora-A was enhanced by EGF treatment in a bi-phase manner. Total lysates from EGF treated A431 cells were harvested for performing the Western blot analysis to demonstrate the expression of Aurora-A. The time-points indicated the duration of EGF treatment. ␣-Tubulin was used as a loading control. (B) Five colorectal cancer cell lines were treated with EGF for 2 (LS174T) or 3 hrs (SW480, SW620, HT29 and HCT116), and then Western Blot analysis was performed. (C) LS174T cells were treated with EGF for various times as indicated (left) or treated with 0, 30 or 60 ng/ml EGF for 2 hrs (right). The lysates were analysed as in (B
The PI3K/Akt/mTOR and MEK/ERK pathways regulate the EGF-induced Aurora-A protein translation
It was well established that the activated mTOR pathway regulates the mRNA translation through the phosphorylation of its downstream targets such as eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and the ribosomal protein S6 kinase (S6K) [11]. To further demonstrate that the EGF signal increases the Aurora-A expression via translational regulation, the mTOR signal pathway was analysed under EGF stimulus. From Fig. 5A, EGF signal augmented the expression of Aurora-A and the phosphorylation forms of Akt, mTOR, p70S6K and 4E-BP1 were increased (compare lanes 1 and 2). It indicated that the addition of EGF might turn on the mTOR pathway to activate the translational machine. To address it, the EGF-mediated activation of mTOR pathway was blocked by rapamycin treatment. The result showed that the EGF-induced Aurora-A protein increase was abolished (Fig. 5A, compare lanes 5 and 6). On the other hand, we had demonstrated that the Akt and ERK signalling pathways were involved in the expression of Aurora-A under EGF treatment (Fig. 1F). By treating cells with U0126 and wortmannin to inhibit the Akt and ERK pathways respectively, the recruitment of Aurora-A mRNA to ribosome complex was abolished (Fig. 5B). This result indicated that both Akt and ERK pathways regulate Aurora-A mRNA translation under EGF stimulus. In addition, it would be interesting to check whether these two pathways are interfering the phosphorylation status of mTOR to increase the Aurora-A mRNA translation. Addition of wortmannin inhibited the Akt pathway to block the mTOR phosphorylation (Fig. 5C, compare lanes 7 and 8) and then stopped the translation as expected
Fig. 3 EGF does not alter the Aurora-A mRNA level in human colorectal cancer cell lines. (A) Serum-starved LS174T cells were treated with EGF for 3 hrs, and total RNA was harvested. The expression levels of Aurora-A and GAPDH mRNA were detected by RT-PCR. The lower panel, serum-starved cells were treated with EGF for different time-points, and the expression level of Aurora-A mRNA was quantified by real-time RT-PCR and normalized with RPL13A (ribosomal protein L 13A). The mean Ϯ S.D. (error bars) was obtained from three independent experiments. (B) Neither U0126 nor wortmannin changed the expression level of Aurora A mRNA under EGF treatment. The expression of Aurora-A mRNA was analysed as in (A). (C) Cells were transiently transfected with the
and 3 hrs. The protein level of Aurora-A was measured by Western blot analysis. Relative protein levels of Aurora-A were normalized to GAPDH. And the quantitative results from three independent experiments was shown below. (B) The expression level of Cdh1 under EGF treated (ϩ) or not (-) was examined by Western blot analysis. (C) 35 S-methionine labelled Aurora-A was immunoprecipitated from LS174T cell lysates by anti-Aurora-A antibodies. The immunoprecipitated product was separated by 10% SDS-PAGE and analysed by radiography. (D) Equal amounts of EGF-stimulated cell lysates were used for the ribosomal protein S6-immunoprecipitation assay. The amount of Aurora-A mRNA in the S6-IP complex was analysed by RT-PCR. Quantitative results are shown in the right panel. The mean Ϯ S.D. was obtained from three independent experiments. (w, water control; ***, P Ͻ 0.001). (E) Amounts of Aurora A mRNA in the S6-IP complexes of SW480, HT29, HCT116 and A431 cells were analysed as described in (C). (w, water control). translation efficiency under EGF stimulation. Moreover, EGF enhanced the report gene expression only in the construct containing exon 2 splicing form in LS174T cells
Discussion
Deregulation of Aurora-A is highly correlated with tumour progression and the poor prognosis [3, 4] . Known instances of Aurora-A overexpression in cancers are through gene amplification, RNA transcriptional up-regulation and prolonged protein stability [18, 19] (Fig. 1) . [20, 21] . This phenomenon was also observed in cancers in which the Aurora-A protein was overexpressed [22] . Our study was designed to investigate the relationship between the overexpression of EGFR and Aurora-A in tumour cells. There are two routes for the EGF/EGFR signalling pathway: the traditional/cytoplasmic signalling pathway and a novel nuclear translocation pathway [23] . Previously, we demonstrated that EGF increased the expression of Aurora-A mRNA through the nuclear EGFR pathway. When cells were treated with EGF, the activated EGFR is translocated into the nucleus and acts as a transcription activator to interact with STAT5 to increase the expression of the Aurora-A gene in EGFR-overexpressing tumours or cells [13] . Besides, we observed a bi-phase increase in Aurora-A protein expression in A431 cells after treatment with EGF for 2 and 24 hrs, Fig. 4D. (C lanes 1-2) . And the amount of Aurora-A or Aurora-B mRNA in the S6-IP complexes were examined (lanes [3] [4] [5] [6] . w: H2O negative control.
The constitutive activation of EGFR is proposed to play a role in chromosome instability
Fig. 5 Activation of the ERK and Akt signalling pathways is important for EGF-increased Aurora-A overexpression. (A) In LS174T cells, the expression of Aurora-A, the activation of mTOR (p-mTOR/S2448) and its substrates, 70S6K (p-p70S6K/T389) and 4E-BP1 (p-4E-BP1/T70), were activated by EGF treatment (lanes 1-2). The addition of the mTOR inhibitor, rapamycin, blocked EGF effect on Aurora-A protein expression (lanes 3-6). (B) The amount of Aurora-A mRNA in the S6-IP complexes of U0126-or wortmannin pre-treated cells was analysed by RT-PCR as described in
respectively (Fig. 1A) . Using U0126 to inhibit the ERK signalling pathway, the expression of Aurora-A only decreased in the early stage, not the late stage, of EGF treatment (Fig. 1G) . This indicates that another mechanism may exist, in addition to the nuclear EGFR pathway, which regulates Aurora-A expression under EGF treatment. To address this hypothesis, LS174T cells, which overexpress the EGFR but not exhibit the nuclear EGFR pathway (Fig. 1B, (Fig. 1) , but not the amount of Aurora-A mRNA (Fig. 3) . Furthermore, the ribosomal S6 protein immunoprecipitation assay showed increased binding of Aurora-A mRNA with the ribosome complex which activates its translation under EGF treatment (Fig. 4D) [24] . The PI3K/Akt signalling pathway occurs at an early stage of cancer formation [11] , and it is activated by stimulation of extracellular signals, including the EGFR, insulin-like growth factor-1 receptor, integrin and the Gprotein-coupled receptor [25] . One of the well-known pathways promoted the survival of cancer cells by activating mTOR/S6K is through the increasing protein translation, and then lead to the effects on the cell cycle progression [11, 25, 26] 
